We are live on !
Find out more
Abingworth Portfolio holdings
AUM
$304M
Turnover
0%
1-Year Est. Return
95.02%
This Fund
S&P 500
This Quarter Est. Return
+20.14%
1 Year Est. Return
+95.02%
3 Year Est. Return
+186.67%
5 Year Est. Return
+346.26%
10 Year Est. Return
–
AUM
$220M
AUM Growth
-$14.8M
(-6.3%)
Cap. Flow
-$32.1M
Cap. Flow % of AUM
Cap. Flow %
-14.58%
Top 10 Holdings %
Top 10 Hldgs %
95.12%
Holding
19
New
2
Increased
1
Reduced
2
Closed
3
Avg Time Held
1
year
Top 10 Avg Time Held
0.8
years
Top 20 Avg Time Held
1
year
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
|
+$8.62M |
| 2 |
INNL
Innocoll Holdings plc Ordinary Shares
INNL
|
+$6.16M |
| 3 |
ChemoCentryx, Inc.
CCXI
|
+$837K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Supernus Pharmaceuticals
SUPN
|
+$27.8M |
| 2 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$13.2M |
| 3 |
CEMP
Cempra, Inc.
CEMP
|
+$3.37M |
| 4 |
HPTX
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
|
+$2.87M |
| 5 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
+$495K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.98% |
| 2 | Miscellaneous | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
SIEN
1
DELISTED
Sientra, Inc.
SIEN
| $55.2M | 25.03% |
219,901
| – | – |
2014 Q4
2 quarters
|
|
2
Protara Therapeutics
TARA
$161M
| $36M | 16.36% |
50,447
| – | – |
2014 Q4
2 quarters
|
|
|
PRTK
3
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $33.5M | 15.21% |
1,301,413
| – | – |
2014 Q4
2 quarters
|
|
4
Amarin Corp
AMRN
$492M
| $19.8M | 8.99% |
404,374
| – | – |
2013 Q2
8 quarters
|
|
|
EVAR
5
DELISTED
Lombard Medical, Inc.
EVAR
| $15.1M | 6.86% |
3,473,452
| – | – |
2014 Q3
3 quarters
|
|
|
CEMP
6
DELISTED
Cempra, Inc.
CEMP
| $14.7M | 6.69% |
428,935
-95,350
| -18% | -$3.37M |
2013 Q2
8 quarters
|
|
|
DRNA
7
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $13.2M | 5.98% |
945,757
-26,977
| -3% | -$495K |
2014 Q1
5 quarters
|
|
|
TBRA
8
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
| $10.2M | 4.61% |
+589,244
| New | +$8.62M |
2015 Q2
0 quarters
|
|
|
INNL
9
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
| $7.95M | 3.61% |
+555,555
| New | +$6.16M |
2015 Q2
0 quarters
|
|
|
ZGNX
10
DELISTED
Zogenix, Inc.
ZGNX
| $3.92M | 1.78% |
291,902
| – | – |
2013 Q2
8 quarters
|
|
|
ANTH
11
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
| $3.77M | 1.71% |
54,749
| – | – |
2013 Q2
8 quarters
|
|
12
DELISTED
Regulus Therapeutics
RGLS
| $3.59M | 1.63% |
2,728
| – | – |
2014 Q1
5 quarters
|
|
|
13
DELISTED
ChemoCentryx, Inc.
CCXI
| $1.77M | 0.8% |
215,000
+105,300
| +96% | +$837K |
2015 Q1
1 quarter
|
|
14
Achieve Life Sciences
QUIT
$710M
| $1.41M | 0.64% |
274
| – | – |
2013 Q2
8 quarters
|
|
15
Decoy Therapeutics
DCOY
$714K
| – | – |
0
| – | – |
2015 Q1
1 quarter
|
|
|
ZLCS
16
DELISTED
ZALICUS INC COM NEW
ZLCS
| $45K | 0.02% |
7,896
| – | – |
2014 Q4
2 quarters
|
|
|
17
DELISTED
Supernus Pharmaceuticals
SUPN
| – | – |
-2,303,462
| Closed | -$27.8M | – |
|
|
PTLA
18
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| – | – |
-347,349
| Closed | -$13.2M | – |
|
|
HPTX
19
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
| – | – |
-62,500
| Closed | -$2.87M | – |
|
Similar funds
LDFR
MPAM
CDIA
GTCM
Abingworth's Q2 2015 Portfolio in Review
As of Q2 2015, Abingworth held 19 positions worth $220M, down 6.3% from $235M the previous quarter. Its ten largest holdings account for 95% of the portfolio.
Abingworth withdrew a net $32.1M in Q2 2015, closing 3 positions and reducing 2 holdings. Its most notable exit was Supernus Pharmaceuticals, an estimated $27.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous.
Against the trend, Abingworth opened a new position in Tobira Therapeutics, Inc. Common Stock worth $10.2M.
- Abingworth's largest Q2 2015 buy was Tobira Therapeutics, Inc. Common Stock: 589,244 shares worth $10.2M.
- Abingworth added most to ChemoCentryx, Inc. in Q2 2015, an estimated $837K increase.
- Abingworth's biggest Q2 2015 reduction was Cempra, Inc., cutting an estimated $3.37M.
- Abingworth fully exited Supernus Pharmaceuticals in Q2 2015, selling an estimated $27.8M.
- Abingworth's ten largest holdings make up 95% of its $220M portfolio in Q2 2015.
- Abingworth opened 2 new positions and closed 3 in Q2 2015.
- Abingworth's portfolio value fell 6.3% quarter-over-quarter to $220M.
Based on Abingworth's 13F filing for Q2 2015, filed 14 Aug 2015.